Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 65 | 2023 | 1324 | 7.370 |
Why?
|
| HIV Infections | 99 | 2024 | 5097 | 6.240 |
Why?
|
| Antiretroviral Therapy, Highly Active | 32 | 2020 | 472 | 2.910 |
Why?
|
| Viral Load | 36 | 2022 | 819 | 2.410 |
Why?
|
| Anti-Retroviral Agents | 21 | 2024 | 551 | 2.210 |
Why?
|
| Pregnancy Complications, Infectious | 11 | 2024 | 529 | 2.180 |
Why?
|
| South Africa | 98 | 2024 | 7596 | 2.100 |
Why?
|
| CD4 Lymphocyte Count | 44 | 2022 | 656 | 1.940 |
Why?
|
| Adult | 86 | 2024 | 5913 | 1.930 |
Why?
|
| Humans | 108 | 2024 | 14537 | 1.830 |
Why?
|
| Female | 87 | 2024 | 9103 | 1.650 |
Why?
|
| Male | 77 | 2022 | 6754 | 1.590 |
Why?
|
| Algorithms | 8 | 2021 | 106 | 1.450 |
Why?
|
| Treatment Outcome | 30 | 2022 | 889 | 1.290 |
Why?
|
| Middle Aged | 46 | 2021 | 3601 | 1.140 |
Why?
|
| Medication Adherence | 8 | 2021 | 151 | 1.120 |
Why?
|
| Cohort Studies | 34 | 2024 | 967 | 1.110 |
Why?
|
| Young Adult | 35 | 2024 | 2498 | 1.080 |
Why?
|
| Infectious Disease Transmission, Vertical | 7 | 2024 | 472 | 1.030 |
Why?
|
| Adolescent | 32 | 2022 | 2985 | 1.030 |
Why?
|
| Tuberculosis | 5 | 2020 | 543 | 0.990 |
Why?
|
| CD4-Positive T-Lymphocytes | 7 | 2016 | 151 | 0.930 |
Why?
|
| Organophosphonates | 6 | 2014 | 45 | 0.930 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2016 | 324 | 0.910 |
Why?
|
| Adenine | 6 | 2014 | 91 | 0.900 |
Why?
|
| Lost to Follow-Up | 8 | 2021 | 62 | 0.900 |
Why?
|
| HIV-1 | 9 | 2019 | 1260 | 0.840 |
Why?
|
| Prospective Studies | 17 | 2024 | 1160 | 0.800 |
Why?
|
| Stavudine | 5 | 2014 | 78 | 0.760 |
Why?
|
| Sarcoma, Kaposi | 4 | 2014 | 53 | 0.750 |
Why?
|
| Time Factors | 15 | 2020 | 507 | 0.720 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 370 | 0.690 |
Why?
|
| Proportional Hazards Models | 13 | 2020 | 163 | 0.680 |
Why?
|
| Ambulatory Care Facilities | 8 | 2022 | 125 | 0.660 |
Why?
|
| Antitubercular Agents | 2 | 2012 | 322 | 0.650 |
Why?
|
| Tenofovir | 9 | 2018 | 171 | 0.610 |
Why?
|
| Continuity of Patient Care | 4 | 2021 | 33 | 0.600 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2020 | 187 | 0.600 |
Why?
|
| Prevalence | 14 | 2020 | 1192 | 0.580 |
Why?
|
| Retrospective Studies | 16 | 2019 | 799 | 0.580 |
Why?
|
| Primary Health Care | 6 | 2020 | 240 | 0.570 |
Why?
|
| Ambulatory Care | 6 | 2022 | 54 | 0.560 |
Why?
|
| HIV Seropositivity | 4 | 2017 | 265 | 0.560 |
Why?
|
| Pregnancy | 13 | 2024 | 1862 | 0.550 |
Why?
|
| Risk Factors | 18 | 2019 | 1475 | 0.530 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 59 | 0.530 |
Why?
|
| HIV | 6 | 2018 | 380 | 0.520 |
Why?
|
| National Health Programs | 5 | 2022 | 78 | 0.510 |
Why?
|
| Patient Compliance | 6 | 2017 | 120 | 0.500 |
Why?
|
| Health Services Accessibility | 4 | 2023 | 280 | 0.450 |
Why?
|
| Herpesviridae Infections | 1 | 2013 | 2 | 0.440 |
Why?
|
| Eligibility Determination | 5 | 2021 | 16 | 0.440 |
Why?
|
| Herpesvirus 8, Human | 1 | 2013 | 14 | 0.430 |
Why?
|
| RNA, Viral | 3 | 2012 | 303 | 0.410 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 11 | 0.400 |
Why?
|
| Coinfection | 5 | 2016 | 276 | 0.390 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 239 | 0.390 |
Why?
|
| Treatment Failure | 8 | 2017 | 175 | 0.380 |
Why?
|
| Isoniazid | 1 | 2012 | 110 | 0.370 |
Why?
|
| Age Factors | 5 | 2019 | 370 | 0.350 |
Why?
|
| Incidence | 12 | 2020 | 685 | 0.330 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 7 | 0.320 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 18 | 0.320 |
Why?
|
| Hepatitis B | 4 | 2012 | 125 | 0.300 |
Why?
|
| Urban Population | 6 | 2013 | 257 | 0.300 |
Why?
|
| Treatment Refusal | 1 | 2007 | 13 | 0.290 |
Why?
|
| Postpartum Period | 3 | 2017 | 85 | 0.290 |
Why?
|
| Office Visits | 2 | 2017 | 6 | 0.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2013 | 118 | 0.280 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2019 | 115 | 0.270 |
Why?
|
| Risk Assessment | 7 | 2017 | 225 | 0.250 |
Why?
|
| Time-to-Treatment | 3 | 2020 | 42 | 0.250 |
Why?
|
| Child, Preschool | 6 | 2020 | 1748 | 0.240 |
Why?
|
| Zambia | 2 | 2024 | 115 | 0.240 |
Why?
|
| Infant | 6 | 2024 | 2244 | 0.240 |
Why?
|
| Africa South of the Sahara | 2 | 2023 | 353 | 0.240 |
Why?
|
| Drug Monitoring | 2 | 2015 | 55 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 256 | 0.230 |
Why?
|
| Public Sector | 7 | 2022 | 82 | 0.230 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 21 | 0.230 |
Why?
|
| Child | 6 | 2020 | 2242 | 0.220 |
Why?
|
| Age Distribution | 3 | 2019 | 107 | 0.220 |
Why?
|
| Guideline Adherence | 2 | 2020 | 43 | 0.220 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 411 | 0.210 |
Why?
|
| Peer Group | 1 | 2022 | 14 | 0.210 |
Why?
|
| Survival Analysis | 5 | 2015 | 149 | 0.210 |
Why?
|
| Point-of-Care Testing | 3 | 2019 | 71 | 0.210 |
Why?
|
| Patient Selection | 2 | 2019 | 40 | 0.200 |
Why?
|
| Machine Learning | 1 | 2022 | 22 | 0.200 |
Why?
|
| Mortality | 2 | 2020 | 104 | 0.200 |
Why?
|
| Government Programs | 2 | 2019 | 30 | 0.190 |
Why?
|
| Sex Factors | 3 | 2013 | 227 | 0.190 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2013 | 195 | 0.190 |
Why?
|
| Health Facilities | 1 | 2021 | 40 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 244 | 0.180 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 39 | 0.180 |
Why?
|
| Critical Pathways | 1 | 2019 | 2 | 0.170 |
Why?
|
| Adolescent Health | 1 | 2019 | 15 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2019 | 35 | 0.160 |
Why?
|
| Kenya | 4 | 2020 | 183 | 0.160 |
Why?
|
| Health Policy | 1 | 2020 | 140 | 0.160 |
Why?
|
| Social Stigma | 1 | 2019 | 80 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2018 | 6 | 0.150 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2018 | 9 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 64 | 0.150 |
Why?
|
| Dideoxynucleosides | 1 | 2018 | 29 | 0.150 |
Why?
|
| Prenatal Care | 2 | 2024 | 147 | 0.150 |
Why?
|
| Body Mass Index | 3 | 2014 | 321 | 0.140 |
Why?
|
| Quality of Life | 1 | 2019 | 177 | 0.140 |
Why?
|
| Motivation | 1 | 2017 | 59 | 0.140 |
Why?
|
| Papanicolaou Test | 1 | 2017 | 29 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 11 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2017 | 26 | 0.140 |
Why?
|
| Medical Audit | 1 | 2017 | 26 | 0.140 |
Why?
|
| Community Health Services | 1 | 2017 | 58 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 33 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2016 | 33 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.130 |
Why?
|
| Zidovudine | 2 | 2013 | 59 | 0.130 |
Why?
|
| Hospitals | 1 | 2016 | 103 | 0.130 |
Why?
|
| Health Resources | 2 | 2013 | 66 | 0.130 |
Why?
|
| Lamivudine | 2 | 2013 | 89 | 0.130 |
Why?
|
| Program Development | 1 | 2015 | 32 | 0.120 |
Why?
|
| Pharmacies | 1 | 2015 | 1 | 0.120 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 9 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 125 | 0.120 |
Why?
|
| Logistic Models | 2 | 2013 | 254 | 0.120 |
Why?
|
| Patient Care | 1 | 2014 | 10 | 0.120 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 278 | 0.120 |
Why?
|
| Public Health | 1 | 2015 | 124 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2014 | 4 | 0.120 |
Why?
|
| Neoplasms | 1 | 2016 | 147 | 0.110 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2014 | 27 | 0.110 |
Why?
|
| Benzoxazines | 1 | 2014 | 123 | 0.110 |
Why?
|
| Data Collection | 2 | 2015 | 86 | 0.110 |
Why?
|
| Nevirapine | 1 | 2014 | 146 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 56 | 0.110 |
Why?
|
| Hypertension | 1 | 2018 | 419 | 0.110 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 1 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2013 | 10 | 0.110 |
Why?
|
| Viral Proteins | 1 | 2013 | 30 | 0.110 |
Why?
|
| Linear Models | 1 | 2013 | 83 | 0.110 |
Why?
|
| Antibodies, Viral | 3 | 2012 | 284 | 0.110 |
Why?
|
| Prognosis | 4 | 2017 | 199 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2013 | 40 | 0.110 |
Why?
|
| Risk | 1 | 2013 | 87 | 0.110 |
Why?
|
| Postnatal Care | 1 | 2013 | 13 | 0.110 |
Why?
|
| Registries | 2 | 2012 | 91 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 171 | 0.100 |
Why?
|
| Aged | 4 | 2021 | 1740 | 0.100 |
Why?
|
| Women's Health | 1 | 2012 | 41 | 0.100 |
Why?
|
| Biomarkers | 4 | 2016 | 327 | 0.100 |
Why?
|
| Adipocytes | 1 | 2012 | 23 | 0.100 |
Why?
|
| Pregnancy Rate | 1 | 2012 | 8 | 0.100 |
Why?
|
| Candidiasis, Oral | 1 | 2012 | 8 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2024 | 1479 | 0.100 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2008 | 48 | 0.100 |
Why?
|
| Nurse Administrators | 1 | 2011 | 9 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 253 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2015 | 329 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 7 | 0.100 |
Why?
|
| Malnutrition | 1 | 2012 | 56 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 57 | 0.090 |
Why?
|
| Kidney | 1 | 2011 | 46 | 0.090 |
Why?
|
| Penile Diseases | 1 | 2011 | 2 | 0.090 |
Why?
|
| Condylomata Acuminata | 1 | 2011 | 4 | 0.090 |
Why?
|
| Africa | 1 | 2012 | 376 | 0.090 |
Why?
|
| Mass Screening | 1 | 2013 | 245 | 0.090 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2011 | 31 | 0.090 |
Why?
|
| Influenza B virus | 1 | 2011 | 42 | 0.090 |
Why?
|
| Papillomaviridae | 1 | 2011 | 34 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 54 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 74 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2009 | 31 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 144 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 188 | 0.080 |
Why?
|
| Counseling | 2 | 2021 | 143 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 435 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 385 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2011 | 374 | 0.070 |
Why?
|
| Self Report | 2 | 2017 | 114 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 253 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2017 | 101 | 0.060 |
Why?
|
| Patient Dropouts | 2 | 2017 | 18 | 0.060 |
Why?
|
| Africa, Southern | 2 | 2014 | 91 | 0.060 |
Why?
|
| Survival Rate | 2 | 2014 | 96 | 0.060 |
Why?
|
| Disease Progression | 2 | 2014 | 154 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.050 |
Why?
|
| Comorbidity | 2 | 2017 | 188 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2013 | 26 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 468 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2012 | 89 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 279 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 106 | 0.050 |
Why?
|
| Text Messaging | 1 | 2021 | 25 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 217 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 80 | 0.040 |
Why?
|
| DNA, Viral | 2 | 2012 | 165 | 0.040 |
Why?
|
| North America | 1 | 2019 | 11 | 0.040 |
Why?
|
| Latin America | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 16 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 56 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 3 | 0.040 |
Why?
|
| Hepatitis B virus | 2 | 2012 | 157 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 203 | 0.040 |
Why?
|
| Laboratories | 1 | 2018 | 47 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2017 | 6 | 0.040 |
Why?
|
| Health Education | 1 | 2017 | 35 | 0.040 |
Why?
|
| Physical Examination | 1 | 2017 | 10 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2017 | 16 | 0.040 |
Why?
|
| Disclosure | 1 | 2017 | 25 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 34 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 156 | 0.030 |
Why?
|
| Medically Underserved Area | 1 | 2016 | 13 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 7 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 321 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 74 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 65 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 124 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 89 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2016 | 40 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2017 | 215 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 121 | 0.030 |
Why?
|
| Fever | 1 | 2015 | 26 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 19 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 480 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 29 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2015 | 49 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 82 | 0.030 |
Why?
|
| Alkynes | 1 | 2014 | 117 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2014 | 123 | 0.030 |
Why?
|
| Viremia | 1 | 2014 | 66 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2013 | 8 | 0.030 |
Why?
|
| Energy Intake | 1 | 2013 | 24 | 0.030 |
Why?
|
| International Cooperation | 1 | 2013 | 50 | 0.030 |
Why?
|
| Motor Activity | 1 | 2013 | 46 | 0.030 |
Why?
|
| Anemia | 1 | 2013 | 41 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 105 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2013 | 179 | 0.030 |
Why?
|
| Educational Status | 1 | 2013 | 68 | 0.030 |
Why?
|
| Gestational Age | 1 | 2013 | 80 | 0.030 |
Why?
|
| Weight Gain | 1 | 2013 | 77 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2012 | 6 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 31 | 0.030 |
Why?
|
| Glucose | 1 | 2012 | 45 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 41 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 22 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 44 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 40 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2013 | 79 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 38 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 133 | 0.020 |
Why?
|
| Body Composition | 1 | 2013 | 153 | 0.020 |
Why?
|
| Inflammation | 1 | 2012 | 104 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 53 | 0.020 |
Why?
|
| Malawi | 1 | 2011 | 87 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 127 | 0.020 |
Why?
|
| Molecular Typing | 1 | 2011 | 12 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 9 | 0.020 |
Why?
|
| Oropharynx | 1 | 2011 | 17 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 2011 | 23 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 23 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 44 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 77 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 24 | 0.020 |
Why?
|
| Didanosine | 1 | 2010 | 11 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 272 | 0.020 |
Why?
|
| Lopinavir | 1 | 2010 | 137 | 0.020 |
Why?
|
| Ritonavir | 1 | 2010 | 137 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 442 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2009 | 26 | 0.020 |
Why?
|
| Liver | 1 | 2008 | 74 | 0.020 |
Why?
|